Citius Pharma: Mino-Lok Phase 3 trial meets primary endpoint (p=0.0006) in CLABSI/CRBSI

Citius Pharmaceuticals, Inc.

Primary endpoint: time to catheter failure significantly delayed for Mino-Lok vs control (p=0.0006); hazard ratio 0.53.
Median time-to-failure for control arm: 33 days; Mino-Lok arm median not reached (NE; CI 50 days-NE).
Secondary endpoint overall success: 57.1% Mino-Lok vs 37.7% control (p=0.0025).
No drug-related serious adverse events reported; safety profile supports well-tolerated designation.
Company plans to engage with FDA to determine next regulatory steps for Mino-Lok.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.